Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add…
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial CellsLONDON, UK / ACCESSWIRE…
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning…
Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigueLatest Phase 3 trial achieved primary endpoint (p=0.00005)Potential…
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and…
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel…
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose…
Mississauga, Ontario--(Newsfile Corp. - February 13, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging player in…
Masimo MightySat® Medical Provides Clinically Proven Masimo SET® Pulse Oximetry to Consumers for Medical Use Without a PrescriptionIRVINE, Calif.--(BUSINESS WIRE)--Masimo…
Masimo MightySat® Medical Provides Clinically Proven Masimo SET® Pulse Oximetry to Consumers for Medical Use Without a PrescriptionIRVINE, Calif.--(BUSINESS WIRE)--Masimo…